药物联合辅助治疗小儿重症肺炎的临床效果

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (24 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨药物联合辅助治疗小儿重症肺炎的临床效果。方法对我院2015年4月～2017年4月收治的80例小儿重症肺炎患儿的临床资料进行统计分析，依据治疗方法的不同分为常规治疗组（n=40）和常规治疗结合多巴胺联合酚妥拉明辅助治疗组（辅助治疗组，n=40）两组。对两组患儿的临床效果、主要临床表现持续时间及住院时间、不良反应发生情况进行比较。结果辅助治疗组患儿治疗总有效率为95.0%，显著高于常规治疗组的82.5%（P＜0.05），发热、咳嗽、气促、肺部啰音持续时间及住院时间均显著短于常规治疗组，差异均有统计学意义（P＜0.05）；辅助治疗组患儿不良反应发生率为7.5%，常规治疗组患儿的不良反应发生率为5.0%，两组差异无统计学意义（P＞0.05）。结论多巴胺联合酚妥拉明辅助治疗小儿重症肺炎的效果显著，不良反应少，值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	梁瑞添

关键词 ：多巴胺, 酚妥拉明联合辅助治疗, 小儿重症肺炎, 疗效, 不良反应

Abstract：ObjectiveTo explore the clinical effect of drug in combination as an adjuvant therapy in children with severe pneumonia.MethodsFrom April 2015 to April 2017,the clinical data of 80 children with severe pneumonia in our hospital were statistically analyzed.According to the different therapeutic methods,these childrens were evenly divided into routine treatment group and routine treatment combined with Dopamine and Phentolamine group(adjuvant therapy group).The clinical efficacy,duration of main clinical manifestations,hospital stay,and incidence of adverse reactions were statistically analyzed.ResultsIn the adjuvant therapy group,the total effectiveness rate was 95.0%,which was greatly higher than that in routine treatment group accounting for 82.5%(P＜0.05).The duration of fever,cough,dyspnea,and lung rale,and hospital stay were significantly shorter than those in the routine treatment group,the differences were statistically significant(P＜0.05).The incidence of adverse reactions was 7.5%in the adjuvant treatment group and 5.0%in the conventional treatment group,which was not displayed a significant difference between the two groups(P＞0.05).ConclusionThe effect of dopamine combined with phentolamine in the treatment of severe pneumonia in children is remarkable with few adverse reactions，worthy of clinical application.

Key words： Dopamine Phentolamine combination adjuvant treatment Severe pneumonia in children Curative effect Adverse reaction

引用本文:

梁瑞添. 药物联合辅助治疗小儿重症肺炎的临床效果[J]. 中国当代医药, 2018, 25(2): 86-88.
LIANG Rui-tian. Clinical effect of drug in combination as an adjuvant therapy in children with severe pneumonia. 中国当代医药, 2018, 25(2): 86-88.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I2/86

[1]	叶竹梅.中药联合纳洛酮治疗小儿重症肺炎临床观察[J].中国中医急症，2014，23（2）：267，270.
[2]	李合云，郭正红，陈文利.人免疫球蛋白联合盐酸氨溴索治疗小儿重症肺炎的临床价值[J].中国医药科学，2015，5（2）:58-60.
[3]	文昌菊.多巴胺联合多巴酚丁胺在小儿重症肺炎治疗中的疗效分析[J].中外医学研究，2011，9（1）：122-123.
[4]	任章平，高明.盐酸氨溴索联合酚妥拉明治疗小儿重症肺炎 90 例疗效观察[J].现代诊断与治疗，2012，23（7）：930-931.
[5]	黄朝鸿.酚妥拉明联合阿拉明治疗小儿重症肺炎的临床观察[J].中国当代医药，2013，20（29）：100-101.
[6]	张学军.护理干预在小儿重症肺炎并发呼吸衰竭中的临床作用[J].西部中医药，2014，27（8）：134-135.
[7]	李丁科，赖陈三，温伟军，等.小剂量多巴胺联合多巴酚丁胺辅助治疗小儿重症肺炎的临床效果及安全性[J].现代诊断与治疗，2016，27（18）：3368-3370.
[8]	范徐威.俯卧位机械通气辅助药物治疗小儿重症肺炎临床观察[J].现代诊断与治疗，2017，28（1）：43-45.
[9]	Nguyen VH，Dubot-Pérès A，Russell FM，et al.Acute respiratory infections in hospitalized children in Vientiane，Lao PDR-the importance of Respiratory Syncytial Virus[J].Sci Rep，2017，7（1）：9318.
[10]	Nunes SEA，Minamisava R，Vieira MADS，et al.Hospitalization costs of severe bacterial pneumonia in children：comparative analysis considering different costing methods[J].Einstein Sao Paulo，2017，15（2）：212-219.
[11]	Bahceci Erdem S，Nacaroglu HT，Isgüder R，et al.Pulmonary complications of chemical pneumonia：a case report[J].Arch Argent Pediatr，2017，115（4）：e245-e248.
[12]	Yazdani R，Abolhassani H，Asgardoon M，et al.Infectious and Noninfectious Pulmonary Complications in Patients With Primary Immunodeficiency Disorders[J].J Investig Allergol Clin Immunol，2017，27（4）：213-224.
[13]	Wi SW，Lee SJ，Kang EK，et al.Ileal Perforation with Norovirus Gastroenteritis in a 3-Month-Old Infant[J].Pediatr Gastroenterol Hepatol Nutr，2017，20（2）：130-133.
[14]	Afzal Z，Kallumadanda S，Wang F，et al.Acute Febrile Illness and Complications Due to Murine Typhus，Texas，USA1，2[J].Emerg Infect Dis，2017，23（8）：1268-1273.
[15]	Rahimi R，Omar E，Tuan Soh TS，et al.A sudden paediatric death due to hand，foot and mouth disease：the importance of vigilance[J].Malays J Pathol，2017，39（2）：167-170.